Cosentyx is a human interleukin-17A antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Adults with active psoriatic arthritis (PsA) Adults with active ankylosing spondylitis (AS)
Secukinumab is a human monoclonal antibody that targets IL-17A cytokine to downregulate inflammation in psoriasis, an autoimmune dermatological disease. The pathophysiology of psoriasis has not been fully established, however it is known that dysregulation of innate and adaptive immune responses plays part in the chronic inflammation associated with the disease. IL-17 represents is a six-membered family (IL-17A to F) of pleiotropic pro-inflammatory cytokines, expression of which is found to be elevated in psoriatic skin. These cytokines act on many different cell types and provide defense against different extracellular pathogens causing fungal or bacterial infections. IL-17 cytokines are produced by many cells involved in immune system defense, such as Th17, mast cells, neutrophils, and dendritic cells - all implicated in promoting inflammation. There is evidence linking IL-17 to pathogenesis of multiple autoimmune diseases including rheumatoid arthritis, spondyloarthritis, psoriasis, Crohn's disease, multiple sclerosis, and even atherosclerosis.
Plaque Psoriasis-
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Most common adverse reactions (greater than 1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.
Serious hypersensitivity reaction to secukinumab or to any of the excipients.
Live vaccines should not be given with Cosentyx
Infections : Serious infections have occurred. Caution should be exercised when considering the use of Cosentyx in patients with a chronic infection or a history of recurrent infection. If a serious infection develops, discontinue Cosentyx until the infection resolves. Tuberculosis (TB) : Prior to initiating treatment with Cosentyx, evaluate for TB. Inflammatory Bowel Disease : Cases of inflammatory bowel disease were observed in clinical trials. Caution should be exercised when prescribing Cosentyx to patients with inflammatory bowel disease. Hypersensitivity Reactions : If an anaphylactic reaction or other serious allergic reaction occurs, discontinue Cosentyx immediately and initiate appropriate therapy.